spidaman, I definitely don't feel that way. Actually it's absurd. But honestly I don't know how high the share price will go immediately or in days after positive TLD/journal publication, because of numerous variables, such as the perception of the general market on data (is it good enough for FDA approval?), how and what is the reflection and interpretation of the mainstream media on the data/news/company, is the news usher in widespread institutional buying, and in what scales?
But safe to say, we have precedent cases to look at in pricing. One familiar example of course is Novocure (NVCR). Note nvcr is a device company which is usually less valued generally than a similar drug/biological product company in the market.
Novocure currently is valued around $10 billion, falling from as high as $25 billion when it peaked about five months ago. So at least $10 billion market valuation for nwbo is readily attainable. That will equate to about $8-10 per share for nwbo.
So I do think share price from $4-5 will be easily reached shortly after positive TLD/publication is announced.
After that how high the price will go it will be everyone's guess, but what I can say is it will go at least as high as $20, given it some time, perhaps a few quarters of steadily increased revenue and profit, if not earlier.
The price will be marked with the following milestones (not exactly in the order below):
manufacturing license, TLD/publication, [UK approval?], substantial financing, multiple trials with other indications, uplist to a major exchange, FDA approval, partnerships/outright buyout, demonstration of Q over Q increased revenues and profits, other major news
In the meantime, it will be rational and reasonable excitement and speculation on the trials and approvals of other indications using DCVax-L and DCVax-D, because of the nature of MOAs which should be able to duplicate on other indications, if not all, at least some.
I will retain most of my shares for a long time. GL!
